No Data
Iovance Shareholders Approve Expanded Capital Flexibility and Governance
Iovance Biotherapeutics Climbs After Conditional Amtagvi Approval in Australia
Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, Tumor-Derived Autologous T Cell Immunotherapy, For Previously Treated Advanced Melanoma
Express News | Iovance’s Amtagvi® (Lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Iovance Biotherapeutics Pushes Cell Therapy Platform Into Solid Tumor Market | NASDAQ:IOVA
Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001